Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis

Slide: 29 of 37

Potential Harms of rhGH Treatment to Patients With CF: Cancer Risk (2)

Studies that investigated cancer risk in rhGH-treated patients with CF measured two investigational biomarkers of cancer risk: IGF-I (insulin-like growth factor I) and IGFBP-3 (insulin-like growth factor-binding protein-3). Increases in IGF-I that are 100 ng/mL greater than baseline or control  levels may indicate increased risk of cancer. Elevations in IGFBP-3 that are >1,000 ng/mL have been linked to increased cancer risk.

There is no consensus on the predictive value of these growth factors for evaluating cancer risk.